Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › temporomandibular disorder

Temporomandibular disorder

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for temporomandibular disorder

7 trials tracked for temporomandibular disorder: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 8 citations.

7Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 3 Other / NA 2
  1. Phase 3 Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles Completed · 8 cited
  2. Phase 4 Efficacy of Naproxen-codeine, Naproxen+Dexamethasone, and Naproxen on Myofascial Pain Completed
  3. Phase 2 Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder Completed
  4. Phase 2 Effectiveness of Photobiomodulation and Manual Therapy Alone or Combined in TMD Patients Completed
  5. Phase 2 Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Completed
  6. N/A The Effectiveness of a Physiotherapy Technique in Patients With Chronic Myofascial Temporomandibular Disorder Completed
Show 1 more trials
  1. N/A Assessing a New Jaw Support Device During Third Molar Extractions Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Temporomandibular disorder: what the trials found

Clinical trials have evaluated various pharmacological and procedural interventions for temporomandibular disorder, including naproxen sodium in various combinations (with codeine phosphate or dexamethasone), paracetamol, and Botulinum toxin type A.

Data regarding Botulinum toxin type A showed no statistically significant differences across groups in terms of changes in jaw pain on the Visual Analog Scale (VAS) 3, improvements in jaw function as measured by the Jaw Function Limitation Scale 3, or changes in Maximum Interincisal Opening (MIO) 3.

Recent results — preliminary, needs further review

  • A 5% lidocaine/0.02% estradiol compound cream showed statistically significant improvements in self-reported physical health via the SF12v2 survey, though it did not produce significant changes in pain scores during the Tampon Test or on the SF-MPQ scale.
  • Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for five treatments showed no statistically significant differences in pain severity, pain interference, or average daily reported pain scores at 20 weeks.

For the clinician treating this condition

  • Botulinum toxin type A did not demonstrate statistically significant improvements in jaw pain (VAS), functional limitations, or maximum opening compared to other interventions.
  • The lidocaine/estradiol compound cream showed a significant impact on physical health scores despite non-significant results in specific pain scales.

AI synthesis of 1 cited trial, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Electroacupuncture alleviates pain in patients with temporomandibular disorder while maintaining a good safety record
Anesthesiology & Pain Medicine Sys. Review
Electroacupuncture alleviates pain in patients with temporomandibular disorder while maintaining a good safety record Electroacupuncture may help relieve pain for people with temporomandibular disorder
This narrative review evaluates electroacupuncture for temporomandibular disorder pain. The authors conclude that electroacupuncture is an e…
Electroacupuncture appears to be a safe option for reducing pain in patients with temporomandibular disorder, though more research is needed…
Frontiers May 29, 2026